# 510(k) Summary (Summary of Safety and Effectiveness)

This summary of the $5 1 0 ( \mathbf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

# Applicant Name

SEP 11 2012

John Rizos, Regulatory Affairs Project Manager   
Regulatory Affairs   
Abbott Laboratories Diagnostics Division   
Dept 9V6, AP5N-2   
100 Abbott Park Road   
Abbott Park, IL 60064   
Telephone Number: (847) 935-1813   
Fax Number: (847) 937-4836   
Date Summary prepared: September 7, 2012

# Device Name

ARCHITECT 2nd Generation Testosterone ARCHITECT 2nd Generation Testosterone Calibrators ARCHITECT 2nd Generation Testosterone Controls

Reagents   
Classification Name: Testosterone test system   
Trade Name: ARCHITECT 2nd Generation Testosterone   
Common Name: Testosterone   
Governing Regulation: 862.1680   
Device Classification: Class I, reserved   
Classification Panel: Clinical Chemistry   
Product Code: CDZ   
Calibrators   
Classification Name: Calibrator   
Trade Name: ARCHITECT 2nd Generation Testosterone Calibrators   
Common Name: Calibrator   
Governing Regulation: 862.1150   
Device Classification: Class II   
Classification Panel: Clinical Chemistry   
Product Code: JIT   
Controls   
Classification Name: Quality Control Material (assayed and unassayed)   
Trade Name: ARCHITECT 2nd Generation Testosterone Controls   
Common Name: Control   
Governing Regulation: 862.1660   
Device Classification: Class I , reserved   
Classification Panel: Clinical Chemistry   
Product Code: JJX

# Predicate Device

Roche Elecsys Testosterone IIassay (k093421)

# Intended Use of Device

The ARCHITECT 2nd Generation Testosterone assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of testosterone in human serum and plasma. Measurements of testosterone are used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in females, hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and adrenogenital syndromes.

The ARCHITECT 2nd Generation Testosterone Calibrators are for the calibration of the ARCHITECT i System when used for the quantitative determination of testosterone in human serum and plasma.

The ARCHITECT 2nd Generation Testosterone Controls are for the verification of the accuracy and precision of the ARCHITECT $i$ System when used for the quantitative determination of testosterone in human serum and plasma.

# Description of Device

# ARCHITECT 2nd Generation Testosterone Reagents

The ARCHITECT 2nd Generation Testosterone Reagent Kit consists of 100 $\lvert 1 \times 1 0 0 \rangle$ or 400 $( 4 \times 1 0 0 )$ tests. Each kit contains 1 or 4 bottle(s) each of Microparticles, Conjugate, Assay Specific Diluent, and Specimen Diluent.

Microparticles - 1 or 4 Bottle(s) $( 6 . 6 \mathrm { m L } )$ Anti-Testosterone (sheep, monoclonal) coated microparticles in BIS Tris buffer with protein (bovine) stabilizer. Minimum concentration: $0 . 1 \%$ solids. Preservative: ProClin 300.

Conjugate $^ { - 1 }$ or 4 Bottle(s) $( 6 . 9 \mathrm { m L }$ Testosterone acridinium-labeled conjugate in BIS Tris buffer with surfactant stabilizer. Minimum concentration: 6.5 nmol/L. Preservative: ProClin 300.

Assay Specific Diluent  1 or 4 Bottle(s) $( 2 5 . 0 \mathrm { m L } )$ Testosterone Assay Diluent containing phosphate and glycine in citrate buffer. Preservative: ProClin 300.

Specimen Diluent  1 or 4 Bottle(s) $1 2 . 2 \mathrm { m L }$ Testosterone Specimen Diluent containing PBS buffer. Preservative: ProClin 300.

# ARCHITECT 2nd Generation Testosterone Calibrators

Each ARCHITECT 2nd Generation Testosterone Calibrator Kit contains 6 Bottles $( 4 . 0 \mathrm { m L }$ each) of ARCHITECT 2nd Generation Testosterone Calibrators A-F. Calibrator A contains PBS buffer. Calibrators B through F contain testosterone in PBS buffer. All calibrators contain a protein (bovine) stabilizer. Preservative: ProClin 300.

The calibrators are manufactured at the following concentrations:

<table><tr><td rowspan=2 colspan=1>Calibrator</td><td rowspan=1 colspan=3>Concentration</td></tr><tr><td rowspan=1 colspan=1>nmol/L</td><td rowspan=1 colspan=1>ng/dL</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Cal A</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Cal B</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>2.88</td><td rowspan=1 colspan=1>0.03</td></tr><tr><td rowspan=1 colspan=1>Cal C</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>5.77</td><td rowspan=1 colspan=1>0.06</td></tr><tr><td rowspan=1 colspan=1>Cal D</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>46.14</td><td rowspan=1 colspan=1>0.46</td></tr><tr><td rowspan=1 colspan=1>Cal E</td><td rowspan=1 colspan=1>12.50</td><td rowspan=1 colspan=1>360.50</td><td rowspan=1 colspan=1>3.60</td></tr><tr><td rowspan=1 colspan=1>Cal F</td><td rowspan=1 colspan=1>30.00</td><td rowspan=1 colspan=1>865.20</td><td rowspan=1 colspan=1>8.64</td></tr></table>

# ARCHITECT 2nd Generation Testosterone Controls

Each ARCHITECT 2nd Generation Testosterone Control Kit contains 3 Bottles $( 8 . 0 \mathrm { m L }$ each) of ARCHITECT 2nd Generation Testosterone Controls. The Low, Medium, and High Controls contain testosterone in PBS buffer with a protein (bovine) stabilizer. Preservative: ProClin 300.

The controls are at the following concentrations:

<table><tr><td rowspan=2 colspan=1>Control</td><td rowspan=1 colspan=6>.      Target Concentration / Range</td></tr><tr><td rowspan=1 colspan=2>nmol/L</td><td rowspan=1 colspan=2>ng/dL</td><td rowspan=1 colspan=2>ng/mL</td></tr><tr><td rowspan=1 colspan=1>Control L</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.16 - 0.46</td><td rowspan=1 colspan=1>8.94</td><td rowspan=1 colspan=1>4.61 - 13.27</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.05 - 0.13</td></tr><tr><td rowspan=1 colspan=1>Control M</td><td rowspan=1 colspan=1>2.42</td><td rowspan=1 colspan=1>1.52 - 3.32</td><td rowspan=1 colspan=1>69.79</td><td rowspan=1 colspan=1>43.62 - 95.96</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.44 - 0.96</td></tr><tr><td rowspan=1 colspan=1>Control H</td><td rowspan=1 colspan=1>7.58</td><td rowspan=1 colspan=1>4.74 - 10.42</td><td rowspan=1 colspan=1>218.61</td><td rowspan=1 colspan=1>136.63 -300.59</td><td rowspan=1 colspan=1>2.18</td><td rowspan=1 colspan=1>1.37 - 2.99</td></tr></table>

# Comparison of Technological Characteristics

The ARCHITECT 2nd Generation Testosterone assay utilizes chemiluminescent microparticle immunoassay (CMIA) technology for the quantitative determination of testosterone in human serum and plasma. The Roche Elecsys Testosterone II assay utilizes electrochemiluminescence immunoassay technology ("ECLIA") and is intended for use on Elecsys and cobas e immunoassay analyzers.

<table><tr><td colspan="3" rowspan="1">Reagent Kit Similarities and Differences</td></tr><tr><td colspan="1" rowspan="1">Characteristics</td><td colspan="1" rowspan="1">Submission DeviceARCHITECT 2ndGeneration Testosterone</td><td colspan="1" rowspan="1">Predicate DeviceRoche ElecsysTestosterone II (k093421)</td></tr><tr><td colspan="1" rowspan="1">Intended Use andIndications for Use</td><td colspan="1" rowspan="1">Immunoassay for the in vitroquantitative determination oftestosterone in human serumand plasma.Measurements of testosteroneare used in the diagnosis andtreatment of disordersinvolving the male sexhormones (androgens),including primary andsecondary hypogonadism,delayed or precociouspuberty, impotence in malesand, in females, hirsutism(excessive hair) andvirilization (masculinization)due to tumors, polycysticovaries, and adrenogenitalsyndromes.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">ARCHITECT i System(immunoassay analyzer)</td><td colspan="1" rowspan="1">Elecsys and cobas eimmunoassay analyzers</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Chemiluminescence(CMIA)</td><td colspan="1" rowspan="1">Electrochemiluminescence(ECLIA)</td></tr><tr><td colspan="1" rowspan="1">Specimen type</td><td colspan="1" rowspan="1">Serum and plasma</td><td colspan="1" rowspan="1">Serum and plasma</td></tr><tr><td colspan="1" rowspan="1">Expected Values</td><td colspan="1" rowspan="1">Males (21-49) :47.01 - 980.56 ng/dL•Males (≥ 50 years of age):127.18-1020.36 ng/dLFemales (21-49):7.21-79.31 ng/dLFemales ( 50 years of age):8.65-36.92 ng/dL</td><td colspan="1" rowspan="1">•Males (20-49):249 - 836 ng/dL Males (≥ 50):193 - 740 ng/dLFemales (20-49):8.40 - 48.1 ng/dL Females (≥ 50):2.90 - 40.8 ng/dLIn addition, a reference rangestudy using pediatricpopulation (95 males and 100females) under 18 years old,who were in goodendocrinological health wasperformed.</td></tr><tr><td colspan="1" rowspan="1">Measuring Interval</td><td colspan="1" rowspan="1">Measuring interval is definedas the range of values inng/dL (nmol/L) which meetsthe acceptable performancefor both imprecision and biasacross all available assay filedilutions. The range was4.33 ng/dL (0.15 nmol/L)(Limit of Quantitation - LoQ)to 1500.00 ng/dL(52.01 nmol/L).</td><td colspan="1" rowspan="1">Measuring Range:2.50 - 1500 ng/dL or0.087 - 52.0 nmol/L(defined by the limit ofdetection and the maximumof the master curve). Valuesbelow the limit of detectionare reported as &lt; 2.50 ng/dLor &lt; 0.087 nmol/L. Valuesabove the measuring range arereported as &gt; 1500 ng/dL or &gt;52.0 nmol/L</td></tr><tr><td colspan="1" rowspan="1">LoBLoD</td><td colspan="1" rowspan="1">LoB: 1.73 ng/dL (0.06nmol/L)</td><td colspan="1" rowspan="1">LoB: 1.20 ng/dL or 0.42nmol/L</td></tr><tr><td colspan="1" rowspan="1">LoQ</td><td colspan="1" rowspan="1">LoD: 2.67 ng/dL (0.10nmol/L)LoQ: 4.33 ng/dL (0.15nmol/L)</td><td colspan="1" rowspan="1">LoD: 2.50 ng/dL or 0.087nmol/LLoQ: 12.0 ng/dL or 0.416nmol/L</td></tr><tr><td colspan="3" rowspan="1">Components:</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Microparticles:1 or 4 Bottle(s) (6.6 mL)Anti-Testosterone (sheep,monoclonal) coatedmicroparticles in BIS Trisbuffer with protein (bovine)stabilizer. Minimumconcentration: 0.1% solids.Preservative: ProClin 300.</td><td colspan="1" rowspan="1">M:Streptavidin-coatedmicroparticles (transparentcap), 1 bottle, 6.5mL:Streptavidin-coatedmicroparticles 0.72 mg/mL,preservative.</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Conjugate: 1 or 4 Bottle(s)(6.9 mL) Testosteroneacridinium-labeled conjugatein BIS Tris buffer withsurfactant stabilizer.Minimum concentration: 6.5nmol/L. Preservative:ProClin 300.</td><td colspan="1" rowspan="1">R1:Anti-testosterone-Ab~biotin(gray cap), 1 bottle, 10mL:Biotinylated monoclonal anti-testosterone antibody (sheep)40 ng/mL; releasing reagent2-bromoestradiol; MES buffer50 mmol/L, pH 6.0;preservative.</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Assay Specific Diluent:1 or 4 Bottle(s) (25.0 mL)Testosterone Assay Diluentcontaining phosphate andglycine in citrate buffer.Preservative: ProClin 300.</td><td colspan="1" rowspan="1">R2:Testosterone-peptide~Ru(bpy) 2* (black cap), 1bottle, 9 mL: Testosteronederivative, labeled withruthenium complex 1.5ng/mL; MES buffer 50mmol/L, pH 6.0; preservative.</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Specimen Diluent:1 or 4 Bottle(s) (12.2 mL)Testosterone SpecimenDiluent containing PBSbuffer. Preservative:ProClin 300.</td><td colspan="1" rowspan="1">NA</td></tr></table>

<table><tr><td rowspan=1 colspan=5>Calibrators: Similarities and Differences:</td></tr><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=3>Submission DeviceARCHITECT 2ndGeneration Testosterone</td><td rowspan=1 colspan=1>Predicate DeviceRoche ElecsysTestosterone II (k093421)</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=3>The ARCHITECT 2ndGeneration TestosteroneCalibrators are for thecalibration of theARCHITECT i System whenused for the quantitativedetermination of testosteronein human serum and plasma.</td><td rowspan=1 colspan=1>The Elecsys TestosteroneCalSetII is intended for thecalibration of the quantitativetestosterone assay on theElecsys immunoassayanalyzer systems.</td></tr><tr><td rowspan=9 colspan=1>Levels</td><td rowspan=2 colspan=3>6 levelsnmol/L ng/dLng/mL</td><td rowspan=9 colspan=1>The calibration curve isinstrument-specificallygenerated by 2-pointcalibration and a master curveprovided via the reagentbarcode. Testosterone IICalSet II -2 levels.</td></tr><tr><td rowspan=1 colspan=1>nmol/L</td><td rowspan=1 colspan=1>ng/dL</td><td rowspan=1 colspan=1>ng/mL</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>2.88</td><td rowspan=1 colspan=1>0.03</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>5.77</td><td rowspan=1 colspan=1>0.06</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>46.14</td><td rowspan=1 colspan=1>0.46</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>12.50</td><td rowspan=1 colspan=1>360.50</td><td rowspan=1 colspan=1>3.60</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>30.00</td><td rowspan=1 colspan=1>865.20</td><td rowspan=1 colspan=1>8.64</td></tr><tr><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Components</td><td rowspan=1 colspan=3>6 Bottles (4.0 mL each) ofARCHITECT 2ndGeneration TestosteroneCalibrators A-F. Calibrator Acontains PBS buffer.Calibrators B through Fcontain testosterone in PBSbuffer. All calibrators containa protein (bovine) stabilizer.Preservative: ProClin 300.</td><td rowspan=1 colspan=1>Lyophilized human serumwith 2 testosteroneconcentration levels</td></tr><tr><td rowspan=1 colspan=1>Standardization/Traceability</td><td rowspan=1 colspan=3>Abbott manufactures internalreference standards forARCHITECT.2ndGeneration Testosteroneusing Testosterone ReferenceStandard (USP).Testosterone calibrators aremanufactured gravimetricallyand tested against theseinternal reference standards.</td><td rowspan=1 colspan=1>This method has beenstandardized via ID-GC/MS(Isotope Dilution-GasChromatography/MassSpectrometry).</td></tr></table>

<table><tr><td colspan="3">Controls: Similarities and Differences: Predicate Device</td></tr><tr><td>Characteristics</td><td colspan="2">Submission Device ARCHITECT 2nd Generation Testosterone The ARCHITECT 2nd</td></tr><tr><td>Intended use</td><td colspan="2">Generation Testosterone Controls are for the verification of the accuracy and precision of the ARCHITECT i System when used for the quantitative determination of testosterone in human serum and plasma.</td></tr><tr><td>Matrix and Components ProClin 300.</td><td colspan="2">3 Bottles (8.0 mL each) of ARCHITECT 2nd Generation Testosterone Controls. Low, Medium, and High Controls contain testosterone in PBS buffer with a protein (bovine) stabilizer. Preservative:</td></tr><tr><td colspan="2">High</td><td>3 levels: Low. Medium, and</td><td>2 levels (multi-constituent, concentration variable on lot- to-lot basis)</td></tr><tr><td rowspan="5">Levels</td><td>Targets:</td><td>ng/dL</td><td>ng/mL</td></tr><tr><td>nmol/L</td><td>8.94</td><td>0.09</td></tr><tr><td>L 0.31</td><td>69.79</td><td>0.70</td></tr><tr><td>M 2.42</td><td></td><td></td></tr><tr><td>H</td><td>7.58 218.61</td><td>2.18</td></tr></table>

# 7Summary of Nonclinical Performance

# SPECIFIC PERFORMANCE CHARACTERISTICS

# Precision

The ARCHITECT 2nd Generation Testosterone assay is designed to have a within-laboratory (total) imprecision of $\leq 1 0 \%$ CV for samples with testosterone concentrations $\geq 1 4 . 4 ~ \mathrm { n g / d L }$ to $1 0 0 9 { \mathrm { n g / d L } }$ .

Within-Laboratory Precision

A study was performed based on guidance from the National Committee for Clinical Laboratory Standards (NCCLS) document EP5-A2: Testing was conducted using two instruments, two ARCHITECT 2nd Generation Testosterone Reagent Kit lots, and one lot each of ARCHITECT 2nd Generation Testosterone Calibrators and Controls. Three levels of controls and 1 human serum panel were assayed with a minimum of 2 replicates at 2 separate times per day for 20 different days. The data are summarized in the following table.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>InstrumentReagent Lot n</td><td rowspan=2 colspan=1>InstrumentReagent Lot n</td><td rowspan=2 colspan=1>n</td><td rowspan=2 colspan=1>Meanng/dL</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Within - Laboratory (Total)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=4 colspan=1>Control Level 1</td><td rowspan=2 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.88</td><td rowspan=1 colspan=1>0.456</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>0.477</td><td rowspan=1 colspan=1>4:8</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.24</td><td rowspan=1 colspan=1>0.358</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.472</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=2 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.56</td><td rowspan=1 colspan=1>0.390</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.439</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.02</td><td rowspan=1 colspan=1>[0.459</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.468</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=4 colspan=1>Control Level 2</td><td rowspan=2 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>76.07</td><td rowspan=1 colspan=1>2.339</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>2.734</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>72.07</td><td rowspan=1 colspan=1>2.277</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>2.361</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=2 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>74.24</td><td rowspan=1 colspan=1>2.492</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>.2.661</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>72.86</td><td rowspan=1 colspan=1>1.769</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.684</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=4 colspan=1>Control Level 3</td><td rowspan=2 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>228.38</td><td rowspan=1 colspan=1>4.811</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.993</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>226.67</td><td rowspan=1 colspan=1>4.643</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>6.008</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=2 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>227.22</td><td rowspan=1 colspan=1>5.732</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>7.496</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>229.95</td><td rowspan=1 colspan=1>5.504</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>6.391</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=4 colspan=1>Panel</td><td rowspan=2 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>62.35</td><td rowspan=1 colspan=1>2.287</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>2.379</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>60.72</td><td rowspan=1 colspan=1>1.285</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.796</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=2 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>61.30</td><td rowspan=1 colspan=1>1.888</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>2.184</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>61.53</td><td rowspan=1 colspan=1>1.558</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>2.028</td><td rowspan=1 colspan=1>3.3</td></tr></table>

The ARCHITECT 2nd Generation Testosterone assay is designed to have a Limit of Quantitation (LoQ) of $\leq 4 . 3 3 ~ \mathrm { n g / d L }$ . The LoQ is defined as the lowest analyte concentration that meets an inter-assay imprecision of $< 2 0 \%$ . The LoQ study design was based on guidance from NCCLS document EPi7-A. The observed LoQ for the ARCHITECT 2nd Generation Testosterone assay was $4 . 3 3 ~ \mathrm { n g / d L }$ with an inter-assay CV of $1 5 . 6 \%$ .

In the same study, the Limit of Blank (LoB) and Limit of Detection (LoD) were determined. The LoB was $1 . 7 3 ~ \mathrm { n g / d L }$ and the LoD was $2 . 6 7 \mathrm { n g / d L }$ .

# Measuring Interval (Reportable Range)

Measuring interval is defined as the range of values in ng/dL which meets the acceptable performance for both imprecision and bias across all available assay file dilutions. The range was $4 . 3 3 ~ \mathrm { \mathfrak { n g / d L } }$ (Limit of Quantitation) to $1 5 0 0 . 0 0 \mathrm { n g / d L }$ .

# Linearity

A study was performed based on guidance from the NCCLS document EP6-A. Using an absolute deviation from linearity of $3 . 6 0 5 ~ \mathrm { { n g / d L } }$ for samples with concentrations of $\leq 1 4 . 4 ~ \mathrm { \mathfrak { n g / d L } }$ , and $1 0 \%$ for samples with concentrations $> 1 4 . 4 ~ \mathrm { n g / d L }$ , a linear range of $3 . 8 2 - 1 8 6 2 . 2 7 ~ \mathrm { n g / d L }$ was demonstrated for the ARCHITECT 2nd Generation Testosterone assay which supports the Measuring Interval (Reportable Range) of $4 . 3 3 ~ \mathrm { { n g / d L } }$ to $1 5 0 0 ~ \mathrm { { n g / d L } }$ .

# Interference

Potentially Interfering Endogenous Substances

Potential interference in the ARCHITECT 2nd Generation Testosterone assay from bilirubin, hemoglobin, total protein, triglycerides, biotin, and Sex Hormone Binding Globulin (SHBG) was evaluated to be $< 1 0 \%$ . Interference was demonstrated by a study based on guidance from the CLSI protocol EP7-A2. The data are summarized in the following table.

<table><tr><td rowspan=3 colspan=1>Potentially Interfering EndogenousSubstance</td><td rowspan=3 colspan=2>InterferentConcentration</td><td rowspan=1 colspan=2>% Interference</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Testosterone Concentration</td></tr><tr><td rowspan=1 colspan=1>201.9 ng/dL</td><td rowspan=1 colspan=1>700.8 ng/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=2>20 mg/dL</td><td rowspan=1 colspan=1>-0.2</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=2>20 mg/dL</td><td rowspan=1 colspan=1>-2.0</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=2>500 mg/dL</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=2>12 g/dL</td><td rowspan=1 colspan=1>-4.6</td><td rowspan=1 colspan=1>-7.0</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=2>2000 mg/dL</td><td rowspan=1 colspan=1>-6.5</td><td rowspan=1 colspan=1>-1.1</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=2>30 ng/mL</td><td rowspan=1 colspan=1>-2.1</td><td rowspan=1 colspan=1>-0.8</td></tr><tr><td rowspan=1 colspan=1>SHBG</td><td rowspan=1 colspan=2>200 nmol/L</td><td rowspan=1 colspan=1>-5.3</td><td rowspan=1 colspan=1>-9.1</td></tr></table>

A study was performed based on guidance from the CLSI document   
EP7-A2. Potentially interfering drugs and other compounds were evaluated to determine whether testosterone concentrations were affected when using the ARCHITECT 2nd Generation Testosterone assay. The data are summarized in the following table. NOTE: Test compound concentration is in $\mathsf { n g / m L }$ unless noted otherwise.

<table><tr><td colspan="1" rowspan="3">Test Compound(Drugs)</td><td colspan="1" rowspan="3">TestCompoundConc.ng/mL</td><td colspan="4" rowspan="1">Testosterone Concentration</td></tr><tr><td colspan="2" rowspan="1">201.9 ng/dL</td><td colspan="2" rowspan="1">700.8 ng/dL</td></tr><tr><td colspan="1" rowspan="1">Conc.Diff.</td><td colspan="1" rowspan="1">% Cross-Reactivity</td><td colspan="1" rowspan="1">Conc.Diff.</td><td colspan="1" rowspan="1">% Cross-Reactivity</td></tr><tr><td colspan="1" rowspan="1">Danazol</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">724.19</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">606.24</td><td colspan="1" rowspan="1">0.6</td></tr><tr><td colspan="1" rowspan="1">Dexamethasone</td><td colspan="1" rowspan="1">2,000</td><td colspan="1" rowspan="1">1.12</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-0.58</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Ethisterone</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">**</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">**</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">Mestranol (17a-Ethynylestradiol3 methyl ether)</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">-3.75</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">2.31</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="2">D(-) Norgestrel</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">-16.83</td><td colspan="1" rowspan="1">-0.8</td><td colspan="1" rowspan="1">-12.69</td><td colspan="1" rowspan="1">-0.6</td></tr><tr><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">1072.19</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">783.66</td><td colspan="1" rowspan="1">0.8</td></tr><tr><td colspan="1" rowspan="1">19-nortestosterone(Nandrolone)</td><td colspan="1" rowspan="1">30 nmol/L</td><td colspan="1" rowspan="1">**</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">**</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">Prednisolone</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">2.64</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">5.44</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Prednisone</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">1.92</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-9.59</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Spironolactone</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">0.43</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-4.21</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Testosterone Propionate</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">2843.19</td><td colspan="1" rowspan="1">28.4</td><td colspan="1" rowspan="1">883.00</td><td colspan="1" rowspan="1">8.8</td></tr><tr><td colspan="1" rowspan="1">5a-Androstane-3b,17b-diol</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">477.51</td><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">348.41</td><td colspan="1" rowspan="1">0.3</td></tr><tr><td colspan="1" rowspan="1">Androstenediol</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">-3.11</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-7.94</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Androstenedione</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">177.29</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">121.47</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">Cortisol</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">0.85</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">15.36</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Cortisone</td><td colspan="1" rowspan="1">2,000</td><td colspan="1" rowspan="1">1.06</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">10.11</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">DHEA</td><td colspan="1" rowspan="1">.1,000</td><td colspan="1" rowspan="1">-13.07</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-9.34</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">DHEAS</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">96.65</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">99.94</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Dihydrotestosterone</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">352.85</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">223.05</td><td colspan="1" rowspan="1">0.4</td></tr><tr><td colspan="1" rowspan="1">Epitestosterone</td><td colspan="1" rowspan="1">100 nmol/L</td><td colspan="1" rowspan="1">2.71</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">12.32</td><td colspan="1" rowspan="1">0.4</td></tr><tr><td colspan="1" rowspan="1">Estradiol (17b-Estradiol)</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">8.67</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-5.50</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="3">Test CompoundDrugs)</td><td colspan="1" rowspan="3">TestCompoundConc.ng/mL</td><td colspan="4" rowspan="1">Testosterone Concentration</td></tr><tr><td colspan="2" rowspan="1">201.9 ng/dL</td><td colspan="2" rowspan="1">700.8 ng/dL</td></tr><tr><td colspan="1" rowspan="1">Conc.Diff.</td><td colspan="1" rowspan="1">% Cross-Reactivity</td><td colspan="1" rowspan="1">Conc.Diff.</td><td colspan="1" rowspan="1">% Cross-Reactivity</td></tr><tr><td colspan="1" rowspan="1">Estrone</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">-8.90</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-9.09</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Ethynodiol diacetate</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">-5.44</td><td colspan="1" rowspan="1">-0.1</td><td colspan="1" rowspan="1">-2.19</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">17a-Ethynyl estradiol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">-11.79</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">3.23</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">11 b-Hydroxytestosterone</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">**</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">**</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">11-Ketotestosterone</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">**</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">**</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">Progesterone</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">-1.75</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">18.65</td><td colspan="1" rowspan="1">0.0</td></tr></table>

The cp st bov e easui intrvl and the $\%$ Cross-reactivity could not be calculated.

# Tube Type Matrix Comparison

A study was performed to evaluate the types of blood collection tubes that can be used with the ARCHITECT 2nd Generation Testosterone assay. The tube types were evaluated using the Passing-Bablok regression method to compare each evaluation tube type $\mathrm { ( N } = 5 4 )$ to the control tube type (serum plastic). The data are summarized in the following table.

<table><tr><td>Evaluation Tube Type</td><td>Control Tube (serum plastic) Range (ng/dL)</td><td>Evaluation Tube Range (ng/dL)</td><td>ra</td><td>Intercept (ng/dL)</td><td></td></tr><tr><td>Serum, glass</td><td rowspan="4">14.61-1430.75</td><td>14.42-1469.01</td><td>1.000</td><td>-0.38</td><td>Slope 1.01</td></tr><tr><td>Serum separator, plastic</td><td>14.23-1477.86</td><td>0.999</td><td>-0.42</td><td>0.99</td></tr><tr><td>Serum separator II Advance</td><td>14.32-1419.41</td><td>0.999</td><td>-0.07</td><td>0.98</td></tr><tr><td>Dipotassium EDTA</td><td>13.41-1526.41</td><td>0.997</td><td>-0.96</td><td>1.02</td></tr></table>

a r = Correlation Coefficient

# EXPECTED VALUES

The expected ranges for the ARCHITECT 2nd Generation Testosterone assay were obtained from testing a minimum of 120 samples from apparently healthy individuals in the following categories: normal males, 21-49 years of age with an intact reproductive system, and normal females 21-49 years of age. Additional samples were tested from apparently healthy males and females $( \geq 5 0$ years of age). The data are summarized in the following table.

<table><tr><td rowspan=2 colspan=1>CategoryApparently Healthy</td><td rowspan=2 colspan=1>n</td><td rowspan=2 colspan=1>AgeRange(years)</td><td rowspan=1 colspan=5>Testosteroneng/dL.</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>Min.</td><td rowspan=1 colspan=1>Max.</td><td rowspan=1 colspan=1>5thpercentile</td><td rowspan=1 colspan=1>95thpercentile</td></tr><tr><td rowspan=1 colspan=1>Males(21-49 years of age)</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>21-49</td><td rowspan=1 colspan=1>494.03</td><td rowspan=1 colspan=1>47.01</td><td rowspan=1 colspan=1>980.56</td><td rowspan=1 colspan=1>240.24</td><td rowspan=1 colspan=1>870.68</td></tr><tr><td rowspan=1 colspan=1>Males( 50 years of age)</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>50-77</td><td rowspan=1 colspan=1>442.41</td><td rowspan=1 colspan=1>127.18</td><td rowspan=1 colspan=1>1020.36</td><td rowspan=1 colspan=1>220.91</td><td rowspan=1 colspan=1>715.81</td></tr><tr><td rowspan=1 colspan=1>Females(21-49 years of age)</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>21-49</td><td rowspan=1 colspan=1>24.80</td><td rowspan=1 colspan=1>:7.21</td><td rowspan=1 colspan=1>79.31</td><td rowspan=1 colspan=1>13.84</td><td rowspan=1 colspan=1>53.35</td></tr><tr><td rowspan=1 colspan=1>Females(≥ 50 years of age)</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>50-82</td><td rowspan=1 colspan=1>23.50</td><td rowspan=1 colspan=1>8.65</td><td rowspan=1 colspan=1>36.92</td><td rowspan=1 colspan=1>12.40</td><td rowspan=1 colspan=1>35.76</td></tr></table>

# Method Comparison

The ARCHITECT 2nd Generation Testosterone assay is designed to have a slope of $1 . 0 \pm 0 . 2$ and a correlation coefficient (r) $\operatorname { s f } \geq 0 . 9 5$ for samples with testosterone concentrations ranging from $4 . 3 3 \mathrm { n g / d L }$ (LoQ) to $1 5 0 0 . 0 0 ~ \mathrm { n g / d L }$ when compared to Liquid Chromatography - Tandem Mass Spectrometry (LCMS). A method comparison study was performed based on guidance from the CLSI document EP9-A2-IR using the Passing-Bablok regression method to compare the ARCHITECT 2nd Generation Testosterone assay to the LCMS testosterone method. The data are summarized in the following tables.

ARCHITECT 2nd Generation Testosterone vs. LCMS $\bf ( n = 1 3 8 )$   

<table><tr><td colspan="2">Concentration Range ng/dL</td><td rowspan="2">Correlation Coefficient (r)</td><td rowspan="2">Intercept ng/dL</td><td rowspan="2">95% CIa</td><td rowspan="2">Slope</td><td rowspan="2">95% Cia</td></tr><tr><td>ARCHITECT</td><td>LCMS</td></tr><tr><td>13.74-1429.61</td><td>6.0-1330.00</td><td>0.994</td><td>-3.70</td><td>(-5.00, -1.66)</td><td>1.00</td><td>(0.98, 1.03)</td></tr></table>

a $\mathbf { { C I } } =$ Confidence Interval

ARCHITECT 2nd Generation Testosterone vs. LCMS Female Specimens $( \mathbf { n } = 7 3 )$   

<table><tr><td colspan="2">Concentration Range ng/dL</td><td rowspan="2">Correlation Coefficient (r)</td><td rowspan="2">Intercept ng/dL</td><td rowspan="2">95% CI</td><td rowspan="2">Slope</td><td rowspan="2">95% CIa</td></tr><tr><td>ARCHITECT</td><td>LCMS</td></tr><tr><td>13.74-349.97</td><td>6.0-346.5</td><td>0.985</td><td>2.77</td><td>(0.53, 4.45)</td><td>0.82</td><td>(0.77, 0.88)</td></tr></table>

8 ${ \bf \ddot { C } } { \bf I } =$ Confidence Interval

ARCHITECT 2nd Generation Testosterone vs. LCMS Male Specimens $( \mathbf { n } = \mathbf { 6 5 } )$ EMPY   

<table><tr><td rowspan=1 colspan=2>Concentration Rangeng/dL</td><td rowspan=2 colspan=1>CorrelationCoefficient(r)</td><td rowspan=2 colspan=1>Interceptng/dL</td><td rowspan=2 colspan=1>95%CIa</td><td rowspan=2 colspan=1>Slope</td><td rowspan=2 colspan=1>95%Cra</td></tr><tr><td rowspan=1 colspan=1>ARCHITECT</td><td rowspan=1 colspan=1>LCMS</td></tr><tr><td rowspan=1 colspan=1>86.93-1429.61</td><td rowspan=1 colspan=1>115.0-1330.0</td><td rowspan=1 colspan=1>0.990</td><td rowspan=1 colspan=1>-48.63</td><td rowspan=1 colspan=1>(-62.25, -32.25)</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>(1.07, 1.13)</td></tr></table>

$\mathrm { C I } =$ Confidence Interval

# . Conclusion

The data presented in this premarket notification demonstrates that the ARCHITECT 2nd Generation Testosterone assay performs substantially equivalent to the predicate device, the Roche Elecsys Testosterone II assay (k093421). Accuracy was demonstrated by comparison to a Liquid Chromatography - Tandem Mass Spectrometry (LCMS) reference method. The data presented in the premarket notification provide reasonable assurance that the ARCHITECT 2nd Generation Testosterone assay is safe and effective for the stated intended use.

Abbott Laboratories   
Abbott Laboratories Diagnostics Division   
c/o John Rizos   
Dept 9V6, AP5N-2   
100 Abbott Park Road   
Abbott Park, IL 60064

Re: k120009 Trade Name: ARCHITECT $2 ^ { \mathfrak { n } \mathfrak { d } }$ Generation Testosterone ARCHITECT $2 ^ { \mathfrak { n } \mathfrak { d } }$ Generation Testosterone Calibrators ARCHITECT $2 ^ { \mathsf { n d } }$ Generation Testosterone Controls Regulation Number: 21 CFR $\ S 8 6 2$ .1680 Regulation Name: Testosterone Test System Regulatory Class: Class I, reserved Product Codes: CDZ, JIT, JJX Dated: July 27, 2012 Received: July 30, 2012

Dear Mr. Rizos:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of. the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/6e98e2dd30eb03de0eac16c6be1d90ad64d513c0b07413ea0b1a24643978a8e2.jpg)

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): k120009   
Device Name: ARCHITECT 2nd Generation Testosterone ARCHITECT 2nd Generation.Testosterone Calibrators ARCHITECT 2nd Generation Testosterone Controls

# Indications for Use:

The ARCHITECT 2nd Generation Testosterone assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of testosterone in human serum and plasma. Measurements of testosterone are used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in females, hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and adrenogenital syndromes.

The ARCHITECT 2nd Generation Testosterone Calibrators are for the calibration of the ARCHITECT i System when used for the quantitative determination of testosterone in human serum and plasma.

The ARCHITECT 2nd Generation Testosterone Controls are for the verification of the accuracy and precision of the ARCHITECT i System when used for the quantitative determination of testosterone in human serum and plasma.

Prescription Use _X AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/59eef23693e7e1c55f7f54af72432fcc267e6946e4b9897bfe571a7ccaeccaab.jpg)

Divisigh Sign/Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) k120009